Table II.
Cox regression analysis for miR-505 expression in patients with breast cancer.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Variable | HR | 95% CI | P-value | HR | 95% CI | P-value |
| miR-505 expression | 3.972 | 2.044–7.720 | 0.012 | 5.707 | 2.798–11.638 | 0.001 |
| Age | 1.328 | 0.721–2.446 | 0.364 | 1.032 | 0.544–1.958 | 0.923 |
| Tumor size | 1.398 | 0.807–2.420 | 0.232 | 1.269 | 0.715–2.253 | 0.416 |
| ER status | 1.069 | 0.618–1.849 | 0.811 | 1.023 | 0.566–1.895 | 0.939 |
| PR status | 1.036 | 0.587–1.829 | 0.903 | 1.182 | 0.631–2.215 | 0.601 |
| HER2 status | 1.231 | 0.702–2.159 | 0.469 | 1.232 | 0.669–2.268 | 0.503 |
| Distant metastasis | 1.974 | 0.993–3.927 | 0.022 | 1.985 | 0.965–4.086 | 0.062 |
| TNM stage | 1.678 | 0.976–2.886 | 0.031 | 2.602 | 1.461–4.632 | 0.041 |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; miR-505, microRNA-505; TNM, Tumor-Node-Metastasis; HR, hazard ratio; CI, confidence interval.